Perennial Allergic Rhinitis

11
Pipeline Programs
6
Companies
7
Clinical Trials
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
7
Early DiscoveryClinical DevelopmentMarket

On Market (4)

Approved therapies currently available

U
ALAVERTApproved
loratadine
Unknown Company
oral2002
U
ALVESCOApproved
ciclesonide
Unknown Company
inhalation2008
U
OMNARISApproved
ciclesonide
Unknown Company
nasal2007
U
ZETONNAApproved
ciclesonide
Unknown Company
nasal2012

Competitive Landscape

5 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
loratadinePhase 41 trial
INS37217 Nasal SprayPhase 21 trial
Active Trials
NCT00210015Completed630Est. Apr 2003
NCT00730912Completed261Est. Dec 2008
UP
UCB PharmaBelgium - Brussels
2 programs
2
LevocetirizinePhase 41 trial
levocetirizinePhase 41 trial
Active Trials
NCT00439712Completed60Est. May 2007
NCT00894231Completed30Est. Aug 2009
Faes Farma
Faes FarmaSpain - Leioa
1 program
1
BilastinePhase 31 trial
Active Trials
NCT01127620Completed650Est. Nov 2006
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
CiclesonidePhase 31 trial
Active Trials
NCT00163501Completed600Est. Apr 2005
Alcon
AlconFORT WORTH, TX
1 program
1
Olopatadine 0.6% nasal sprayPhase 31 trial
Active Trials
NCT00578331CompletedEst. Jan 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB Pharmalevocetirizine
Merck & Co.loratadine
UCB PharmaLevocetirizine
AlconOlopatadine 0.6% nasal spray
Faes FarmaBilastine
AstraZenecaCiclesonide
Merck & Co.INS37217 Nasal Spray

Clinical Trials (7)

Total enrollment: 2,231 patients across 7 trials

NCT00894231UCB Pharmalevocetirizine

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

Start: Jan 2009Est. completion: Aug 200930 patients
Phase 4Completed
NCT00730912Merck & Co.loratadine

Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)

Start: Jun 2008Est. completion: Dec 2008261 patients
Phase 4Completed
NCT00439712UCB PharmaLevocetirizine

Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis

Start: Feb 2007Est. completion: May 200760 patients
Phase 4Completed
NCT00578331AlconOlopatadine 0.6% nasal spray

Safety Study of Olopatadine Nasal Spray

Start: Dec 2006Est. completion: Jan 2008
Phase 3Completed
NCT01127620Faes FarmaBilastine

Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension

Start: May 2004Est. completion: Nov 2006650 patients
Phase 3Completed
NCT00163501AstraZenecaCiclesonide

Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)

Start: Dec 2003Est. completion: Apr 2005600 patients
Phase 3Completed
NCT00210015Merck & Co.INS37217 Nasal Spray

A Study in Subjects With Perennial Allergic Rhinitis

Start: Dec 2002Est. completion: Apr 2003630 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space